Michael Didié, Peter Christalla, Michael Rubart, Vijayakumar Muppala, Stephan Döker, Bernhard Unsöld, Ali El-Armouche, Thomas Rau, Thomas Eschenhagen, Alexander P. Schwoerer, Heimo Ehmke, Udo Schumacher, Sigrid Fuchs, Claudia Lange, Alexander Becker, Wen Tao, John A. Scherschel, Mark H. Soonpaa, Tao Yang, Qiong Lin, Martin Zenke, Dong-Wook Han, Hans R. Schöler, Cornelia Rudolph, Doris Steinemann, Brigitte Schlegelberger, Steve Kattman, Alec Witty, Gordon Keller, Loren J. Field, Wolfram-Hubertus Zimmermann
Multilineage potential of PSCs in vitro and in vivo.
(A) RT-PCR analyses of lineage-specific transcripts in differentiating PSCs (PSC line B2). MEFs served as controls. Culture day 7; i.e., 2 days of hanging drop followed by 5 days in suspension culture. (+): Subsequent adhesion culture days. M, 100 bp DNA marker (full uncut gels are shown in the Supplemental Material). (B) EB culture day 22 (PSC line B3): pancytokeratin (pKRT), cytokeratin-18 (KRT18), α-fetoprotein (AFP), neurofilament protein M (NEFM), nebulin (NEB), GATA4. Respective lineage markers (red); nuclei (blue). Scale bars: 20 μm. (C and D) Comparison of teratoma size and composition 3 weeks after s.c. injection of ESCs and PSCs in SCID mice. Teratoma volume was quantified by ultrasonic biomicroscopy (representative image in C; data represent means ± SEM). H&E staining revealed multilineage potential of PSCs, including the capacity to generate cross-striated muscle (inset in D shows magnification of smaller boxed area). Scale bars: 50 μm.